Safety of new oral anticoagulant drugs: a perspective
Authors:
Open Access
- 10 October 2013
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 5 (1) , 8-20
Abstract
The recent development of new oral anticoagulants (NOACs) offers the possibility of efficacy, relative safety and convenience compared with warfarin. This could lead to greater patient compliance, with easier management and improved provision of thromboprophylaxis. Safety whilst using NOACs should be focused on bleeding cases, surgery or on the management of patients receiving anticoagulant therapy with concomitant impairment of renal function, especially since many NOACs are dependent on renal excretion. Thus, if the clearance creatinine indicates severe renal impairment, NOACS will be contraindicated or their dose needs to be changed. In patients who need surgery, there are published protocols of management, depending on the severity of the intervention and renal function. In the case of severe hemorrhage, requiring rapid reversal of the anticoagulant effect and in the absence of specific antidotes, alternatives such as one of the nonspecific haemostatic agents must be considered. Clinical evaluation in bleeding situations and a meticulous risk–benefit appraisal for NOACs is needed, and these procoagulant agents and patients must be monitored closely. This article provides an overview of the pharmacology and potential risks, as well as the efficacy and safety of NOACs.Keywords
This publication has 68 references indexed in Scilit:
- Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2012
- New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complicationsThrombosis and Haemostasis, 2012
- Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit ModelAnesthesiology, 2012
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor DabigatranStroke, 2011
- Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conferenceEP Europace, 2011
- Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agentsJournal of Thrombosis and Haemostasis, 2011
- A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacementThrombosis Research, 2011
- Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration timeThrombosis and Haemostasis, 2011
- Assays for Measuring Rivaroxaban: Their Suitability and LimitationsTherapeutic Drug Monitoring, 2010
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007